Incorporation of positively charged ribonucleic guanidine linkages into oligodeoxyribonucleotides: Development of potent antisense agents

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 7, 2008, Pages 2377-2384

  Park, Myunji ^a   Canzio, Daniele ^a   Bruice, Thomas C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antisense oligonucleotide; Ribonucleic guanidine (RNG); RNG DNA chimera

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BCR ABL PROTEIN; COMPLEMENTARY DNA; GUANIDINE; NUCLEASE; OLIGODEOXYRIBONUCLEOTIDE; PHOSPHATE; RNA; SINGLE STRANDED DNA;

AMINO ACID METABOLISM; AMINO ACID SYNTHESIS; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CHIMERA; CHRONIC MYELOID LEUKEMIA; DNA BINDING; DRUG POTENCY; ENZYME DEGRADATION; NUCLEIC ACID SYNTHESIS; ONCOGENE; PROTEIN CROSS LINKING; SOLID PHASE SYNTHESIS; THERMODYNAMICS;

BASE SEQUENCE; BINDING SITES; DNA; GUANIDINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NUCLEIC ACID CONFORMATION; NUCLEIC ACID DENATURATION; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHATES; RNA;

EID: 41149127949     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.02.063     Document Type: Article

References (44)

1. Uhlmann E., and Peyman A. Chem. Rev. 90 (1990) 543
2. De Mesmaeker A., Haener R., Martin P., and Moser H.E. Acc. Chem. Res. 28 (1995) 366
3. Agrawal S., and Zhao Q.Y. Curr. Opin. Chem. Biol. 2 (1998) 519
4. Thoung N.T., and Helene C. Angew. Chem., Int. Ed. Engl. 32 (1993) 666
5. Cook P.D. Nucleosides Nucleotides 18 (1990) 1141
6. Stein C.A., and Cheng Y.-C. Science 261 (1993) 1004
7. Tseng B.Y., and Ts'o P.O.P. Antisense Res. Dev. 5 (1995) 251
8. Morvan F., Sanghvi Y.S., Perbost M., Vasseur J.-J., and Bellon L. J. Am. Chem. Soc. 118 (1996) 255
9. De Mesmaeker A., Lesueur C., Bevierre M.-O., Waldner A., Fritsch V., and Wolf R.M. Angew. Chem., Int. Ed. Engl. 35 (1996) 2790
10. Bohler C., Nielsen P.E., and Orgel L.E. Nature 376 (1995) 578
11. Veselkov A.G., Demidov V.V., Frank-Kamenetiskii N.D., and Nielsen P.E. Nature 379 (1996) 214
12. Uhimann E., Peyman A., Breipohl G., and Will D.W. Angew. Chem., Int. Ed. Engl. 37 (1998) 2796
13. Peyman A., Uhlmann E., Wagner K., Augustin S., Breipohl G., Will D.W., Schafer A., and Wallmeier H. Angew. Chem., Int. Ed. Engl. 35 (1996) 2636
14. Fujii M., Yoshida K., and Hidaka J. Bioorg. Med. Chem. Lett. 7 (1997) 637
15. Dempcy R.O., Browne K.A., and Bruice T.C. J. Am. Chem. Soc. 117 (1995) 6140
16. Dempcy R.O., Browne K.A., and Bruice T.C. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 6097
17. Dempcy R.O., Almarsson O., and Bruice T.C. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 7864
18. Browne K.A., Dempcy R.O., and Bruice T.C. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 7051
19. Linkletter B.A., Szabo I.E., and Bruice T.C. J. Am. Chem. Soc. 121 (1999) 388
20. Linkletter B.A., Szabo I.E., and Bruice T.C. Bioorg. Med. Chem. 8 (2000) 1893
21. Linkletter B.A., Szabo I.E., and Bruice T.C. Nucleic Acids Res. 29 (2001) 2370
22. Barakar D.A., and Bruice T.C. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 11047
23. Barakar D.A., Kwok Y., Bruice T.W., and Bruice T.C. J. Am. Chem. Soc. 122 (2000) 5244
24. Park M., and Bruice T.C. Bioorg. Med. Chem. Lett. 15 (2005) 3247
25. Park M., Toporowski J.W., and Bruice T.C. Bioorg. Med. Chem. 14 (2006) 1743
26. Dwaine A., Susan J., Yinghui L., Kiran K., Khalil A., Michael A., and David C. Biochemistry 42 (2003) 7967
27. Arya D.P., and Bruice T.C. J. Am. Chem. Soc. 120 (1998) 6619
28. + 999.03.
29. + 448.63.
30. + 720.94.
31. Kojima N., and Bruice T.C. Org. Lett. 2 (2000) 81
32. Kojima N., Szabo I.E., and Bruice T.C. Tetrahedron 58 (2002) 867
33. + 1325.67.
34. + 1449.80.
35. + 1227.56.
36. Oligonucleotide synthesis and purification: All modified oligonucleotides were synthesized on 1.3 μmol scale on Pharmacia Gene Assembler Plus DNA synthesizer. Standard DNA synthesis condition was employed, viz., CPG support and base protected 5′-O-(4,4′-dimethoxytrityl)deoxyribonucleoside-3′-[O-(diisopropylamino)-β-cyanoethylphosramidite] monomers. The phosphoramidite activated oligomer 9.12 was used at an extra monomer position, in order to introduce a guanidium linkage into Oligonucleotides. The standard synthesis cycle was modified to perform an extended coupling (15 min) during the coupling the modified phosphoramidite oligomer 9.12; a coupling efficiency of >95% was observed for this step.
37. Marky L.A., and Breslauer K.J. Biopolymers 26 (1987) 2601
38. Breslauer, K. J. In Methods in Molecular biology; Agrawal, S., Ed.; Humana: Totowa, 1995; Vol. 26, p 347.
39. Gralla J., and Crothers D.M. J. Mol. Biol. 78 (1973) 301
40. Szabo I.E., and Bruice T.C. Bioorg. Med. Chem. 12 (2004) 4233
41. Johnson W.T., Zhang P., and Bergstrom D.E. Nucleic Acids Res. 25 (1997) 559
42. 3CN in 0.1 M TEAA, pH 7.0, for 50 min at a flow rate of 1 mL/min. Reactions without enzyme were run for each oligonucleotide and analyzed by HPLC as controls.
43. Hemavathi C., and Bruice T.C. Bioorg. Med. Chem. Lett. 11 (2001) 2423
44. 2O was added. The aqueous phase was concentrated in vacuo. The residue was purified by RP-HPLC (Altech Macrosphere RP C8 column 0-40% acetonitrile in 3% aqueous acetic acid). Mass spectrometry data for compound 10, 11, 12.{A table is presented}.